
Leidos Hld (LDOS) Stock Forecast & Price Target
Leidos Hld (LDOS) Analyst Ratings
Bulls say
Leidos Holdings Inc. has demonstrated significant improvement in its financial performance, particularly within the Health & Civil segment, where increased exam volumes have led to enhanced margins and scalable growth. The company's EBIT margins have notably increased from 14.5% in 2023 to 22.5% in 2024, with further impressive margins of 24.3% reported in the first half of 2025. Furthermore, the expectation that the Department of Veterans Affairs will reduce its claims backlog to 60,000 by the end of 2025 supports a positive outlook for sustained revenue growth in the near term.
Bears say
Leidos Holdings Inc. is facing a negative outlook primarily due to projected significant declines in margins for the latter half of 2025 compared to the first half. The company's revenue may be further pressured by a potential reduction in medical exam volumes, which constitutes a substantial risk to its margins. Additionally, a deteriorating budget environment could exacerbate these challenges, leading to waning investor sentiment regarding the stock's performance.
This aggregate rating is based on analysts' research of Leidos Hld and is not a guaranteed prediction by Public.com or investment advice.
Leidos Hld (LDOS) Analyst Forecast & Price Prediction
Start investing in Leidos Hld (LDOS)
Order type
Buy in
Order amount
Est. shares
0 shares